Lead Program 2
Metabolic Disease (likely NASH)
Pre-clinicalActive
Key Facts
About Venenum Biodesign
Venenum Biodesign is a preclinical-stage biotechnology company leveraging its proprietary ECLiPS screening technology and a 5.5-million-compound library to discover novel small molecule drugs. Its research is concentrated on two core therapeutic areas: immuno-oncology and metabolic disease, with two lead-stage programs advancing toward developmental candidates. Operating within the integrated Genesis Drug Discovery & Development (GD3) CRO network, the company combines internal discovery capabilities with a partnership-based business model to de-risk and advance its pipeline.
View full company profile